These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33667538)

  • 21. Tofacitinib as a treatment of alopecia areata in adolescents.
    Morales-Miranda AY; Bueno-Arias GM; Aguirre-Félix ÓG; Tovar-Franco R
    Bol Med Hosp Infant Mex; 2019; 76(4):182-187. PubMed ID: 31303654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral tofacitinib for successful treatment of refractory alopecia areata in preschool children.
    Geng SL; Gong T; Ji C; Su HH
    J Eur Acad Dermatol Venereol; 2022 Dec; 36(12):e1055-e1057. PubMed ID: 35876014
    [No Abstract]   [Full Text] [Related]  

  • 23. Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman.
    Mrowietz U; Gerdes S; Gläser R; Schröder O
    Acta Derm Venereol; 2017 Feb; 97(2):283-284. PubMed ID: 27349217
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
    Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
    Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
    [No Abstract]   [Full Text] [Related]  

  • 25. Treatment of Alopecia Areata With Tofacitinib.
    Ibrahim O; Bayart CB; Hogan S; Piliang M; Bergfeld WF
    JAMA Dermatol; 2017 Jun; 153(6):600-602. PubMed ID: 28355451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topical tofacitinib in treatment of alopecia areata.
    Ferreira SB; Ferreira RB; Scheinberg MA
    Einstein (Sao Paulo); 2020; 18():eAI5452. PubMed ID: 32785452
    [No Abstract]   [Full Text] [Related]  

  • 27. Alopecia areata and tofacitinib: a prospective multicenter study from a Saudi population.
    AlMarzoug A; AlOrainy M; AlTawil L; AlHayaza G; AlAnazi R; AlIssa A; AlSheikh A; AlKhalifah A; AlHarithy R
    Int J Dermatol; 2022 Jul; 61(7):886-894. PubMed ID: 34716573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Topical tofacitinib for the treatment of alopecia areata affecting facial hair.
    Kerkemeyer KLS; Sinclair RD; Bhoyrul B
    Br J Dermatol; 2021 Sep; 185(3):677-679. PubMed ID: 33914907
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of systemic minoxidil and tofacitinib combination in treatment-resistant alopecia universalis.
    Dincer D; Tanacan E; Kose Ozkan C
    J Cosmet Dermatol; 2021 Jun; 20(6):1807-1809. PubMed ID: 33098729
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Response to tofacitinib therapy of eyebrows and eyelashes in alopecia areata.
    Liu LY; King BA
    J Am Acad Dermatol; 2019 Jun; 80(6):1778-1779. PubMed ID: 30502414
    [No Abstract]   [Full Text] [Related]  

  • 31. Oral tofacitinib monotherapy in Korean patients with refractory moderate-to-severe alopecia areata: A case series.
    Park HS; Kim MW; Lee JS; Yoon HS; Huh CH; Kwon O; Cho S
    J Am Acad Dermatol; 2017 Nov; 77(5):978-980. PubMed ID: 29029911
    [No Abstract]   [Full Text] [Related]  

  • 32. Low-dose tofacitinib for treating patients with severe alopecia areata: an efficient and cost-saving regimen.
    Chen YY; Lin SY; Chen YC; Yang CC; Lan CE
    Eur J Dermatol; 2019 Dec; 29(6):667-669. PubMed ID: 31903968
    [No Abstract]   [Full Text] [Related]  

  • 33. Tofacitinib for the treatment of alopecia areata in preadolescent children.
    Craiglow BG; King BA
    J Am Acad Dermatol; 2019 Feb; 80(2):568-570. PubMed ID: 30195571
    [No Abstract]   [Full Text] [Related]  

  • 34. An urticarial drug eruption caused by tofacitinib for alopecia universalis.
    Doolan BJ; Cranwell WC; Varigos GA; De Cruz R
    Dermatol Ther; 2019 Jul; 32(4):e12933. PubMed ID: 30977965
    [No Abstract]   [Full Text] [Related]  

  • 35. Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents.
    Liu LY; King BA
    J Investig Dermatol Symp Proc; 2018 Jan; 19(1):S18-S20. PubMed ID: 29273099
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of tofacitinib for treatment of alopecia areata in children: A systematic review and meta-analysis.
    Behrangi E; Barough MS; Khoramdad M; Hejazi P; Koltapeh MP; Goodarzi A
    J Cosmet Dermatol; 2022 Dec; 21(12):6644-6652. PubMed ID: 36177815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata.
    Kennedy Crispin M; Ko JM; Craiglow BG; Li S; Shankar G; Urban JR; Chen JC; Cerise JE; Jabbari A; Winge MC; Marinkovich MP; Christiano AM; Oro AE; King BA
    JCI Insight; 2016 Sep; 1(15):e89776. PubMed ID: 27699252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Apremilast and tofacitinib exert differential effects in the humanized mouse model of alopecia areata.
    Laufer Britva R; Keren A; Paus R; Gilhar A
    Br J Dermatol; 2020 Jan; 182(1):227-229. PubMed ID: 31254391
    [No Abstract]   [Full Text] [Related]  

  • 39. Therapeutic synergy between contact dermatitis from a wig-fixing device and tofacitinib on alopecia areata.
    Lee JS; Yoon HS; Cho S; Park HS
    J Dermatol; 2019 Apr; 46(4):e139-e140. PubMed ID: 30204259
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment outcome of oral tofacitinib and ruxolitinib in patients with alopecia areata: A systematic review and meta-analysis.
    Yu DA; Kim YE; Kwon O; Park H
    Indian J Dermatol Venereol Leprol; 2021; 87(5):621-627. PubMed ID: 34379968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.